Palvella Unveils Promising Phase 2 Data for QTORIN

Palvella Therapeutics ( (PVLA) ) has provided an update.

On May 15, 2026, Palvella Therapeutics reported new data from its Phase 2 TOIVA trial of topical QTORIN rapamycin in cutaneous venous malformations, presented at the 83rd Annual Meeting of the Society for Investigative Dermatology in Chicago. The single-arm, open-label trial showed that all patients with bleeding at baseline achieved statistically significant improvement on the Cutaneous Venous Malformations Investigator Global Assessment Bleeding scale at Week 12, with 100% rated “Much Improved” or “Very Much Improved” and all reporting they were satisfied or very satisfied with treatment.

Baseline qualitative patient interviews from the TOIVA study highlighted the substantial physical, functional, and psychosocial burden of moderate-to-severe cutaneous venous malformations, including pain, swelling, cosmetic concerns, and limitations in daily activities and emotional wellbeing. The findings suggest QTORIN rapamycin could address an unmet need for more than 75,000 individuals in the U.S. by potentially becoming the first approved therapy and a new standard of care for this rare condition, reinforcing Palvella’s positioning in rare dermatologic and vascular malformation markets.

The most recent analyst rating on (PVLA) stock is a Buy with a $220.00 price target. To see the full list of analyst forecasts on Palvella Therapeutics stock, see the PVLA Stock Forecast page.

Spark’s Take on PVLA Stock

According to Spark, TipRanks’ AI Analyst, PVLA is a Neutral.

The score is held down primarily by weak financial performance (zero revenue, widening losses, and continued cash burn) and limited valuation support (negative P/E, no dividend yield provided). These are partially offset by neutral-to-improving technicals and a strong set of recent corporate events, including positive Phase 3 data and strengthened funding, which improve the forward setup despite current fundamental losses.

To see Spark’s full report on PVLA stock, click here.

More about Palvella Therapeutics

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations that currently lack U.S. Food and Drug Administration–approved treatments. The company’s pipeline is built around its patented QTORIN platform, led by QTORIN 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas, alongside QTORIN pitavastatin for disseminated superficial actinic porokeratosis.

Average Trading Volume: 299,269

Technical Sentiment Signal: Buy

Current Market Cap: $1.71B

For a thorough assessment of PVLA stock, go to TipRanks’ Stock Analysis page.